Partnership Breakup Nets $30M For NPS, mGluR For AstraZeneca Oct. 10, 2007 By Donna Young NPS Pharmaceuticals Inc. and AstraZeneca plc mutually agreed to end their six-year partnership to discover and develop drugs targeting metabotropic glutamate receptors (mGluRs). (BioWorld Today)Read More
RSS